Want to see WGS full AI Analyst Report?
WGS Stock Chart & Stats
$59.10
$1.44(2.44%)
At close: 4:00 PM EDT
$59.10
$1.44(2.44%)
Day’s Range― - ―
52-Week Range$32.21 - $170.87
Previous Close$60.5
Volume611.52K
Average Volume (3M)792.87K
Market Cap
$2.46B
Enterprise Value$2.07K
Total Cash (Recent Filing)$132.55M
Total Debt (Recent Filing)$167.40M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Nov 03, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.64
Shares Outstanding29,822,540
10 Day Avg. Volume638,663
30 Day Avg. Volume792,869
Financial Highlights & Ratios
PEG Ratio2.86
Price to Book (P/B)11.35
Price to Sales (P/S)8.18
P/FCF Ratio245.23
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$85.00Price Target Upside43.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.08
Revenue Forecast (FY)$481.93M
Bulls Say, Bears Say
Bulls Say
Sustained Volume GrowthConsistent, high-single-digit to double-digit test volume growth demonstrates durable clinical demand and scale in rare-disease genomics. Higher volumes spread fixed lab costs, improve operating leverage and support revenue expansion over the next 2–3 years as payer coverage continues to normalize.
Durable High Gross MarginsSustained ~70% gross margin indicates attractive unit economics for sequencing and interpretation services. This margin buffer gives management flexibility to invest in RCM, technology and commercial expansion while enabling a clearer path to stable profitability as reimbursements improve.
Material Payer Coverage ExpansionMeaningful, recent payer-policy gains are structural: broader commercial and Medicaid coverage reduces long-term reimbursement risk and increases addressable market. As active policies propagate, realized collections and predictable revenue should improve over multiple quarters.
Bears Say
Negative Operating And Free Cash FlowA return to material cash burn versus the prior year creates persistent funding and execution risk. Negative OCF/FCF constrains reinvestment, may necessitate further debt or equity, and lengthens the time horizon for self-funded scaling even if revenue and margins remain healthy.
Low Outpatient Genome Collection RatesLow collection rates and incomplete submissions create a durable drag on revenue realization and working capital. Even with coverage gains, administrative denials and submission gaps mean collections lag volumes, making cash flow and profitability dependent on sustained RCM execution over many quarters.
Genome Unit-Cost DisadvantageHigher genome reagent and processing costs materially raise blended unit costs, pressuring margins as genome mix rises. Durable margin improvement depends on technology or reagent cost declines and operational gains anticipated in 2027, creating near-term margin risk during scale-up.
GeneDx Holdings News
WGS FAQ
What was Genedx Holdings Corp.’s price range in the past 12 months?
Genedx Holdings Corp. lowest stock price was $32.21 and its highest was $170.87 in the past 12 months.
What is Genedx Holdings Corp.’s market cap?
Genedx Holdings Corp.’s market cap is $2.46B.
When is Genedx Holdings Corp.’s upcoming earnings report date?
Genedx Holdings Corp.’s upcoming earnings report date is Nov 03, 2026 which is in 81 days.
How were Genedx Holdings Corp.’s earnings last quarter?
Genedx Holdings Corp. released its earnings results on Aug 03, 2026. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.188 by $0.198.
Is Genedx Holdings Corp. overvalued?
According to Wall Street analysts Genedx Holdings Corp.’s price is currently Undervalued.
Does Genedx Holdings Corp. pay dividends?
Genedx Holdings Corp. does not currently pay dividends.
What is Genedx Holdings Corp.’s EPS estimate?
Genedx Holdings Corp.’s EPS estimate is 0.07.
How many shares outstanding does Genedx Holdings Corp. have?
Genedx Holdings Corp. has 29,822,540 shares outstanding.
What happened to Genedx Holdings Corp.’s price movement after its last earnings report?
Genedx Holdings Corp. reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.188. Following the earnings report the stock price went up 4.48%.
Which hedge fund is a major shareholder of Genedx Holdings Corp.?
Currently, no hedge funds are holding shares in WGS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GeneDx Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$85.00 (43.82% Upside)
$85.00 (43.82% Upside)
Blogger Sentiment
Bullish
WGS Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 666.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $93.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.44%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.80%
Trailing 12-Months
Company Description
Genedx Holdings Corp.
GeneDx Holdings Corp. functions as a health intelligence firm singularly focused on the individual patient. It aims to revolutionize healthcare delivery by deploying advanced artificial intelligence and machine learning capabilities. These sophisticated algorithms are applied to vast, longitudinal clinical and genomic datasets to construct comprehensive, dynamic models of human health, ultimately defining personalized, optimal pathways for each person's well-being. Through its exclusive Centrellis health intelligence platform, the company gains profound insights into both disease states and overall wellness, enabling it to furnish evidence-based solutions for the most critical medical challenges. Eric Schadt established the corporation in October 2015, and its principal offices are located in Stamford, Connecticut.
WGS Company Deck
WGS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reflects a cautiously optimistic outlook: strong operational performance (record test volumes, revenue growth, return to profitability, margin improvement, and major payer coverage wins) provides clear highlights, while significant near‑term challenges remain around low outpatient collection rates, higher genome unit costs, and timing lags for revenue realization. Management presented a concrete multi‑pronged plan (RCM, payer workflows, technology, commercial investments) and reinforced guidance, expecting meaningful RCM and revenue uplift beginning in Q4 2026 and more substantially in 2027.View all WGS earnings summariesWGS Revenue Breakdown
96.59% Diagnostic test revenue
3.41% Other
WGS Stock 12 Month Forecast
Average Price Target
$85.00
▲(43.82% Upside)
Technical Analysis
Evolent Health
―
10x Genomics
―
Certara
―
SOPHiA GENETICS
―
BrightSpring Health Services, Inc.
―
Ownership Overview
46.37% Insiders
18.82% Mutual Funds
17.60% Other Institutional Investors
1.25% Public Companies and
Individual Investors